SUPPLEMENTAL MATERIAL

TITLE

Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-Marketing Surveillance

AUTHORS

Motoshi WADA[1], MD, PhD*

Shiro NAKAMURA[2], MD, PhD*

Ayako HAYASHI[3], PhD

Rie OTAKE[3], HDS

Masakazu MIYAMOTO[4], MSc

Tomoko TANAKA[5], MD, PhD

* Equal contribution

AUTHORS' AFFILIATIONS

[1] Department of Pediatric Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

[2] The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan

[3] Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan

[4] Marketed Products Development JP, Clinical Science, Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan

[5] Therapeutic Area Strategy Unit GI and Inflammation, Takeda Pharmaceutical Company Limited, Osaka, Japan

AUTHOR FOR CORRESPONDENCE

Motoshi Wada

Department of Pediatric Surgery

Tohoku University Graduate School of Medicine

1-1 Seiryou-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan

Tel: +81 22 717 7237

E-mail: wada@ped-surg.med.tohoku.ac.jp

LIST OF TABLES AND FIGURES

Table S1 Occurrence of adverse events during teduglutide treatment (by preferred term) by seriousness (safety analysis population)

Table S2 Occurrence of adverse drug reactions to teduglutide (by preferred term) by seriousness (safety analysis population)

Table S3 Parenteral support weaning by patient background factor (effectiveness population, N=107)

Table S4 Parenteral support frequency and weaning in adult patients with and without Crohn's disease (effectiveness population, N=107)

Table S5 Parenteral support frequency and weaning in adult patients with and without colon-in-continuity (effectiveness population, N=107)

Table S6 Parenteral support frequency and weaning based on initial dose of teduglutide (effectiveness population, N=107)

Fig. S1 Effectiveness evaluation for adults with short bowel syndrome.

Fig. S2 Effectiveness evaluation for short bowel syndrome in adult patients with Crohn's disease.

Fig. S3 Effectiveness evaluation for short bowel syndrome in adult patients without Crohn's disease.

Fig. S4 Effectiveness evaluation for children with short bowel syndrome: number of days per week of parenteral support at baseline (N=22) and after 6 months of teduglutide (N=23).

Table S1 Occurrence of adverse events during teduglutide treatment (by preferred term) by seriousness (safety analysis population)

	All (N=123)	Adult population (N=96)		Pediatric population (N=27)	
	Total	Total	Serious	Total	Serious
Patients with AEs, n (%)	70 (56.91)	57 (59.38)	24 (25.00)	13 (48.15)	7 (25.93)
Number of AEs[a], n	190	159	46	31	11
Patients with AEs by PT, n (%)					
Abdominal pain	14 (11.38)	10 (10.42)	0	4 (14.81)	1 (3.70)
Abdominal distension	13 (10.57)	11 (11.46)	0	2 (7.41)	0
Stoma complication	10 (8.13)	10 (10.42)	0	0	0
Device-related infection	9 (7.32)	8 (8.33)	8 (8.33)	1 (3.70)	1 (3.70)
Nausea	8 (6.50)	7 (7.29)	1 (1.04)	1 (3.70)	0
Diarrhoea	4 (3.25)	4 (4.17)	1 (1.04)	0	0
Vomiting	4 (3.25)	3 (3.13)	0	1 (3.70)	0
Dehydration	3 (2.44)	3 (3.13)	2 (2.08)	0	0
Dizziness	3 (2.44)	3 (3.13)	2 (2.08)	0	0
Face oedema	3 (2.44)	3 (3.13)	0	0	0
Oedema	3 (2.44)	3 (3.13)	0	0	0
COVID-19	3 (2.44)	2 (2.08)	0	1 (3.70)	0
Injection site pain	3 (2.44)	2 (2.08)	0	1 (3.70)	0
Puncture site erythema	3 (2.44)	2 (2.08)	0	1 (3.70)	0
Abdominal pain lower	2 (1.63)	2 (2.08)	0	0	0
Abdominal pain upper	2 (1.63)	2 (2.08)	0	0	0
Anaemia	2 (1.63)	2 (2.08)	1 (1.04)	0	0
Cholecystitis acute	2 (1.63)	2 (2.08)	2 (2.08)	0	0
Device dislocation	2 (1.63)	0	0	2 (7.41)	1 (3.70)
Fistula discharge	2 (1.63)	2 (2.08)	0	0	0
Flatulence	2 (1.63)	2 (2.08)	0	0	0
Headache	2 (1.63)	2 (2.08)	0	0	0
Ileus	2 (1.63)	1 (1.04)	1 (1.04)	1 (3.70)	1 (3.70)
Inappropriate schedule of product administration	2 (1.63)	1 (1.04)	0	1 (3.70)	0
Oedema peripheral	2 (1.63)	2 (2.08)	0	0	0
Overdose	2 (1.63)	2 (2.08)	0	0	0

	All (N=123)	Adult population (N=96)		Pediatric population (N=27)	
	Total	Total	Serious	Total	Serious
Gastroenteritis	2 (1.63)	0	0	2 (7.41)	1 (3.70)
Pyrexia	2 (1.63)	2 (2.08)	0	0	0
Sepsis	2 (1.63)	1 (1.04)	1 (1.04)	1 (3.70)	1 (3.70)
Septic shock	2 (1.63)	2 (2.08)	2 (2.08)	0	0
Stoma site haemorrhage	2 (1.63)	2 (2.08)	0	0	0
Vascular device infection	2 (1.63)	1 (1.04)	1 (1.04)	1 (3.70)	1 (3.70)
Abdominal abscess	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Acidosis	1 (0.81)	0	0	1 (3.70)	1 (3.70)
Anal fistula	1 (0.81)	1 (1.04)	0	0	0
Arthralgia	1 (0.81)	1 (1.04)	0	0	0
Asthenia	1 (0.81)	1 (1.04)	0	0	0
Back pain	1 (0.81)	1 (1.04)	0	0	0
Blood pressure decreased	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Bone pain	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Catheter site dermatitis	1 (0.81)	0	0	1 (3.70)	0
Catheter site infection	1 (0.81)	0	0	1 (3.70)	1 (3.70)
Catheter site hypoaesthesia	1 (0.81)	1 (1.04)	0	0	0
Catheter site swelling	1 (0.81)	1 (1.04)	0	0	0
Cholecystitis	1 (0.81)	1 (1.04)	1 (1.04)	0	0
C-reactive protein increased	1 (0.81)	1 (1.04)	0	0	0
Constipation	1 (0.81)	0	0	1 (3.70)	0
Decreased appetite	1 (0.81)	0	0	1 (3.70)	0
Duodenal ulcer haemorrhage	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Enterocolitis	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Enterocutaneous fistula	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Fall	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Faeces soft	1 (0.81)	1 (1.04)	0	0	0
Fluid retention	1 (0.81)	1 (1.04)	0	0	0
Frequent bowel movements	1 (0.81)	1 (1.04)	0	0	0
Gastrointestinal motility disorder	1 (0.81)	0	0	1 (3.70)	0
Gastrointestinal stoma complication	1 (0.81)	1 (1.04)	0	0	0
Granulomatosis with polyangiitis	1 (0.81)	1 (1.04)	1 (1.04)	0	0

	All (N=123)	Adult population (N=96)		Pediatric population (N=27)	
	Total	Total	Serious	Total	Serious
Gynecomastia	1 (0.81)	1 (1.04)	0	0	0
Haemoptysis	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Heat illness	1 (0.81)	1 (1.04)	0	0	0
Herpes virus infection	1 (0.81)	1 (1.04)	0	0	0
Hepatitis	1 (0.81)	0	0	1 (3.70)	1 (3.70)
Hyperkalaemia	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Hypervolaemia	1 (0.81)	1 (1.04)	0	0	0
Hypoaesthesia	1 (0.81)	1 (1.04)	0	0	0
Hypoalbuminaemia	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Hypocalcaemia	1 (0.81)	1 (1.04)	0	0	0
Injection site bruising	1 (0.81)	1 (1.04)	0	0	0
Insomnia	1 (0.81)	0	0	1 (3.70)	0
Intestinal haemorrhage	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Lymphadenitis	1 (0.81)	1 (1.04)	0	0	0
Mechanical ileus	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Middle insomnia	1 (0.81)	1 (1.04)	0	0	0
Neck pain	1 (0.81)	0	0	1 (3.70)	0
Oral discomfort	1 (0.81)	1 (1.04)	0	0	0
Platelet count decreased	1 (0.81)	1 (1.04)	0	0	0
Puncture site pain	1 (0.81)	1 (1.04)	0	0	0
Puncture site pruritus	1 (0.81)	0	0	1 (3.70)	0
Pyoderma gangrenosum	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Renal impairment	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Sinusitis	1 (0.81)	1 (1.04)	0	0	0
Skin erosion	1 (0.81)	1 (1.04)	0	0	0
Stoma prolapse	1 (0.81)	1 (1.04)	0	0	0
Stoma site oedema	1 (0.81)	1 (1.04)	0	0	0
Stoma site pain	1 (0.81)	1 (1.04)	0	0	0
Subileus	1 (0.81)	1 (1.04)	0	0	0
Underdose	1 (0.81)	1 (1.04)	0	0	0
Urinary tract infection	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Urine output increased	1 (0.81)	1 (1.04)	0	0	0

	All (N=123)	Adult population (N=96)		Pediatric population (N=27)	
	Total	**Total**	**Serious**	**Total**	**Serious**
Urticaria contact	1 (0.81)	1 (1.04)	0	0	0
Vascular device occlusion	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Vitreous haemorrhage	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Weight decreased	1 (0.81)	1 (1.04)	0	0	0

AE adverse event, *PT* preferred term

[a]The number of AEs is calculated as a single case for multiple occurrences of the same PT in the same patient

Table S2 Occurrence of adverse drug reactions to teduglutide (by preferred term) by seriousness (safety analysis population)

	All (N=123)	Adult population (N=96)		Pediatric population (N=27)	
	Total	Total	Serious	Total	Serious
Patients with ADRs, n (%)	51 (41.46)	44 (45.83)	6 (6.25)	7 (25.93)	3 (11.11)
Number of ADRs[a], n	117	101	8	16	5
Patients with ADRs by PT[b], n (%)					
Abdominal pain	13 (10.57)	10 (10.42)	0	3 (11.11)	1 (3.70)
Abdominal distension	11 (8.94)	10 (10.42)	0	1 (3.70)	0
Stoma complication	8 (6.50)	8 (8.33)	0	0	0
Nausea	7 (5.69)	7 (7.29)	1 (1.04)	0	0
Vomiting	4 (3.25)	3 (3.13)	0	1 (3.70)	0
Diarrhoea	3 (2.44)	3 (3.13)	0	0	0
Face oedema	3 (2.44)	3 (3.13)	0	0	0
Oedema	3 (2.44)	3 (3.13)	0	0	0
Puncture site erythema	3 (2.44)	2 (2.08)	0	1 (3.70)	0
Abdominal pain lower	2 (1.63)	2 (2.08)	0	0	0
Abdominal pain upper	2 (1.63)	2 (2.08)	0	0	0
Dizziness	2 (1.63)	2 (2.08)	1 (1.04)	0	0
Fistula discharge	2 (1.63)	2 (2.08)	0	0	0
Flatulence	2 (1.63)	2 (2.08)	0	0	0
Headache	2 (1.63)	2 (2.08)	0	0	0
Ileus	2 (1.63)	1 (1.04)	1 (1.04)	1 (3.70)	1 (3.70)
Injection site pain	2 (1.63)	2 (2.08)	0	0	0
Oedema peripheral	2 (1.63)	2 (2.08)	0	0	0
Stoma site haemorrhage	2 (1.63)	2 (2.08)	0	0	0
Acidosis	1 (0.81)	0	0	1 (3.70)	1 (3.70)
Arthralgia	1 (0.81)	1 (1.04)	0	0	0
Asthenia	1 (0.81)	1 (1.04)	0	0	0
Back pain	1 (0.81)	1 (1.04)	0	0	0
Cholecystitis	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Cholecystitis acute	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Constipation	1 (0.81)	0	0	1 (3.70)	0
C-reactive protein increased	1 (0.81)	1 (1.04)	0	0	0

	All (N=123)	Adult population (N=96)		Pediatric population (N=27)	
	Total	Total	Serious	Total	Serious
Decreased appetite	1 (0.81)	0	0	1 (3.70)	0
Dehydration	1 (0.81)	1 (1.04)	0	0	0
Device dislocation	1 (0.81)	0	0	1 (3.70)	0
Device related infection	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Enterocutaneous fistula	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Faeces soft	1 (0.81)	1 (1.04)	0	0	0
Frequent bowel movements	1 (0.81)	1 (1.04)	0	0	0
Gastroenteritis	1 (0.81)	0	0	1 (3.70)	1 (3.70)
Gastrointestinal motility disorder	1 (0.81)	0	0	1 (3.70)	0
Gastrointestinal stoma complication	1 (0.81)	1 (1.04)	0	0	0
Gynecomastia	1 (0.81)	1 (1.04)	0	0	0
Hyperkalaemia	1 (0.81)	1 (1.04)	1 (1.04)	0	0
Hypervolaemia	1 (0.81)	1 (1.04)	0	0	0
Hypoaesthesia	1 (0.81)	1 (1.04)	0	0	0
Inappropriate schedule of product administration	1 (0.81)	1 (1.04)	0	0	0
Injection site bruising	1 (0.81)	1 (1.04)	0	0	0
Insomnia	1 (0.81)	0	0	1 (3.70)	0
Middle insomnia	1 (0.81)	1 (1.04)	0	0	0
Oral discomfort	1 (0.81)	1 (1.04)	0	0	0
Overdose	1 (0.81)	1 (1.04)	0	0	0
Platelet count decreased	1 (0.81)	1 (1.04)	0	0	0
Puncture site pain	1 (0.81)	1 (1.04)	0	0	0
Puncture site pruritus	1 (0.81)	0	0	1 (3.70)	0
Pyrexia	1 (0.81)	1 (1.04)	0	0	0
Skin erosion	1 (0.81)	1 (1.04)	0	0	0
Stoma prolapse	1 (0.81)	1 (1.04)	0	0	0
Stoma site oedema	1 (0.81)	1 (1.04)	0	0	0
Stoma site pain	1 (0.81)	1 (1.04)	0	0	0
Sub ileus	1 (0.81)	1 (1.04)	0	0	0

	All (N=123)	Adult population (N=96)		Pediatric population (N=27)	
	Total	**Total**	**Serious**	**Total**	**Serious**
Urine output increased	1 (0.81)	1 (1.04)	0	0	0

ADR adverse drug reaction, *PT* preferred term, *SOC* system organ class

[a]If the same PT occurred more than once in the same case, it is counted as the total number of cases

[b]In cases where the same SOC or PT occurred more than once in the same case, the number of cases was not counted in duplicate

Table S3 Parenteral support weaning by patient background factor (effectiveness population, N=107)

Variable	Applicable patients, n	Weaned at 6 months, n (%)
Sex		
Male	59	3 (5.1)
Female	48	9 (18.8)
Age, years		
<1	0	-
≥1 to ≤9	16	1 (6.3)
≥10 to ≤19	17	3 (17.6)
≥20 to ≤29	7	1 (14.3)
≥30 to ≤39	12	0 (0.0)
≥40 to ≤49	13	3 (23.1)
≥50 to ≤59	23	2 (8.7)
≥60 to ≤69	11	1 (9.1)
≥70 to ≤79	7	1 (14.3)
≥80	1	0 (0.0)
<1	0	-
≥1 to ≤14	24	4 (16.7)
≥15 to ≤64	72	7 (9.7)
≥65	11	1 (9.1)
<1	0	-
≥1 to ≤5	8	1 (12.5)
≥6 to ≤10	10	1 (10.0)
≥11 to ≤14	6	2 (33.3)
≥15	83	8 (9.6)
Height z-score, cm (pediatric only)		
≤−3.0	5	0 (0.0)
>−3.0 to ≤−2.0	4	0 (0.0)
>−2.0 to ≤−1.0	6	1 (16.7)
>−1.0 to ≤0	5	1 (20.0)
>0 to ≤+1.0	1	1 (100.0)
>+1.0 to ≤+2.0	2	0 (0.0)
>+2.0	1	1 (100.0)
Not measured	0	-
Body weight z-score at start of teduglutide, kg (pediatric only)		
≤−3.0	1	0 (0.0)
>−3.0 to ≤−2.0	2	0 (0.0)
>−2.0 to ≤−1.0	9	1 (11.1)
>−1.0 to ≤0	8	2 (25.0)
>0 to ≤+1.0	1	0 (0.0)
>+1.0 to ≤+2.0	0	-
>+2.0	0	-
Not measured	3	1 (33.3)
BMI at start of teduglutide, kg/m^2 (adult only)		
<18.5	37	5 (13.5)
≥18.5 to <25.0	30	1 (3.3)
≥25.0 to <30.0	1	0 (0.0)

Variable	Applicable patients, n	Weaned at 6 months, n (%)
≥30.0 to <35.0	1	1 (100.0)
≥35.0 to <40.0	0	-
≥40.0	0	-
CDAI score at start of teduglutide		
<150	2	0 (0.0)
≥150 to <220	0	-
≥220 to <450	0	-
≥450	1	0 (0.0)
Major cause of massive intestinal resection		
Abdominal adhesions	4	0 (0.0)
Abdominal trauma	0	-
Complex intussusception	0	-
Crohn's disease	44	6 (13.6)
Familial polyposis	0	-
Gastroschisis	3	0 (0.0)
Intestinal angiomatosis	0	-
Intestinal atresia	3	1 (33.3)
Intestinal ischemia of unknown or other etiology	2	0 (0.0)
Volvulus	19	1 (5.3)
Hirschsprung's disease (long-segment type)	6	1 (16.7)
Mesenteric infarction (arterial or venous thrombosis)	3	1 (33.3)
Movement disorder leading to SBS	1	0 (0.0)
Necrotizing enterocolitis	4	0 (0.0)
Radiation enterocolitis	3	1 (33.3)
Surgical complications	5	0 (0.0)
Tumor	1	0 (0.0)
Other	9	1 (11.1)
Smoking history		
Never smoked	74	11 (14.9)
Current smoker	5	0 (0.0)
Former smoker but no longer smoker	17	1 (5.9)
Unknown	11	0 (0.0)
Drinking history		
None	93	12 (12.9)
Yes	6	0 (0.0)
Unknown	8	0 (0.0)
Presence of complications		
None	41	5 (12.2)
Yes	66	7 (10.6)
Use of therapeutic drugs for SBS within 12 months before starting teduglutide		
None	62	3 (4.8)
Yes	45	9 (20.0)
Creatinine clearance, mL/min		
<50	28	2 (7.1)
≥50	62	9 (14.5)
Not measured	17	1 (5.9)

Variable	Applicable patients, n	Weaned at 6 months, n (%)
eGFR, mL/min/1.73 m^2 (adults)		
<15	5	0 (0.0)
≥15 to <30	5	0 (0.0)
≥30 to <45	15	2 (13.3)
≥45 to <60	17	3 (17.6)
≥60 to <90	19	3 (15.8)
≥90	22	0 (0.0)
eGFR, mL/min/1.73 m^2 (pediatric)		
<15	0	-
≥15 to <30	0	-
≥30 to <60	0	-
≥60 to <90	2	0 (0.0)
≥90	22	4 (18.2)
AST at start of teduglutide, U/L		
≤40	69	10 (14.5)
>40	28	1 (3.6)
ALT at start of teduglutide, U/L		
≤40	66	8 (12.1)
>40	31	3 (9.7)
Total bilirubin at start of teduglutide, mg/dL		
≤1.2	86	9 (10.5)
>1.2	8	1 (12.5)
Presence of remnant small intestine		
None	1	0 (0.0)
Yes	106	12 (11.3)
Estimated total length of remaining small intestine, cm		
0	1	0 (0.0)
>0 to <30	26	1 (3.8)
≥30 to ≤70	19	1 (5.3)
>70	43	9 (20.9)
Unknown	18	1 (5.6)
Presence of intact colon		
None	40	5 (12.5)
Yes	67	7 (10.4)
Presence of colonic remnants		
None	30	4 (13.3)
Yes	77	8 (10.4)
Presence of stoma		
None	56	4 (7.1)
Yes	51	8 (15.7)
Type of stoma		
Jejunostomy	18	2 (11.1)
Ileostomy	27	5 (18.5)
Colostomy	5	1 (20.0)
Other	1	0 (0.0)
Colon-in-continuity[a]		
None	50	8 (16.0)

Variable	Applicable patients, n	Weaned at 6 months, n (%)
Yes	57	4 (7.0)
Years of PS before starting teduglutide		
<1	11	2 (18.2)
≥1 to <5	27	5 (18.5)
≥5 to <10	23	0 (0.0)
≥10	40	5 (12.5)
Years of PS at home		
<1	17	3 (17.6)
≥1 to <5	22	2 (9.1)
≥5 to <10	15	1 (6.7)
≥10	21	2 (9.5)
Self-administration		
None	10	1 (10.0)
Yes	97	11 (11.3)
Discontinuation of teduglutide administration		
None	92	12 (13.0)
Yes	15	0 (0.0)
Initial dose of teduglutide		
0.05 mg/kg	78	9 (11.5)
0.025 mg/kg	28	3 (10.7)
Off-label	1	0 (0.0)

ALT alanine aminotransferase, *AST* aspartate aminotransferase, *BMI* body mass index, *CDAI* Crohn's Disease Activity Index, *eGFR* estimated glomerular filtration rate, *PS* parenteral support, *SBS* short bowel syndrome

[a]Colon-in-continuity refers to cases with colonic remnant and stoma type other than jejunostomy or ileostomy, or with colonic remnant and no stoma

Table S4 Parenteral support frequency and weaning in adult patients with and without Crohn's disease (effectiveness population, N=107)

Variable	With Crohn's disease		Without Crohn's disease[a]	
	n	Mean (SD)	n	Mean (SD)
PS dose				
At baseline	41	10,783.6 (10,843.74)	38	8021.6 (5933.73)
At 6 months	41	6702.3 (7419.65)	38	6980.3 (5946.13)
PS reduction from baseline, mL/week	38	–4021.9 (5917.99)	37	–1400.3 (1858.82)
Percent reduction	34	–34.41 (37.498)	37	–20.94 (29.936)
Achieved PS reduction ≥20%, n (%)	34	20 (58.8)	37	12 (32.4)
Days of PS per week				
At baseline	41	5.2 (2.74)	38	6.0 (2.11)
At 6 months	41	4.1 (3.03)	38	5.3 (2.49)
Percent change from baseline to 6 months	38	–1.3 (2.21)	37	–0.7 (1.52)
Weaned at 6 months, n (%)	40	6 (15.0)	38	2 (5.3)

PS parenteral support, *SD* standard deviation

[a]Data for without Crohn's disease contain 1 example of off-label use

Table S5 Parenteral support frequency and weaning in adult patients with and without colon-in-continuity (effectiveness population, N=107)

Variable	With CIC[a]		Without CIC	
	n	Mean (SD)	n	Mean (SD)
PS dose				
At baseline	35	7512.7 (5073.92)	44	11,000.1 (10,830.90)
At 6 months	35	6506.3 (4929.28)	44	7098.3 (7892.89)
PS reduction from baseline, mL/week	34	–1396.0 (1932.86)	41	–3833.6 (5734.40)
Percent reduction	34	–19.61 (29.119)	37	–34.53 (37.224)
Achieved PS reduction ≥20%, n (%)	34	11 (32.4)	37	21 (56.8)
Days of PS per week				
At baseline	35	6.1 (1.96)	44	5.1 (2.77)
At 6 months	35	5.3 (2.42)	44	4.1 (3.04)
Percent change from baseline to 6 months	34	–0.8 (1.53)	41	–1.2 (2.18)
Weaned at 6 months, n (%)	35	1 (2.9)	43	7 (16.3)

CIC colon-in-continuity, *PS* parenteral support, *SD* standard deviation[a]Data for with CIC contain 1 example of off-label use

Table S6 Parenteral support frequency and weaning based on initial dose of teduglutide (effectiveness population, N=107)

Variable	Initial dose of teduglutide					
	0.05 mg/kg		0.025 mg/kg		Off-label	
	n	Mean (SD)	n	Mean (SD)	n	Value
PS dose						
At baseline	75	8631.9 (8110.61)	25	9968.4 (8518.98)	1	11,760.0
At 6 months	74	6181.8 (5822.86)	27	7602.4 (7430.85)	1	10,500.0
PS reduction from baseline, mL/week	71	–2223.7 (3876.81)	24	–2976.9 (5352.16)	1	–1260.0
Percent reduction	67	–20.00 (51.556)	24	–29.66 (37.742)	1	–10.70
Achieved PS reduction ≥20%, n (%)	67	27 (40.3)	24	12 (50.0)	1	0 (0.0)
Days of PS per week						
At baseline	75	6.1 (2.20)	25	5.3 (2.44)	1	7.0
At 6 months	74	5.0 (2.82)	27	4.7 (2.91)	1	7.0
Percent change from baseline to 6 months	71	–1.1 (2.23)	24	–0.8 (1.43)	1	0.0
Weaned at 6 months, n (%)	73	9 (12.3)	27	3 (11.1)	1	0 (0.0)

PS parenteral support, *SD* standard deviation



Fig. S1 Effectiveness evaluation for adults with short bowel syndrome.

a Frequency distribution of parenteral support doses at baseline and after 6 months of teduglutide (N=79). **b** Number of days per week of parenteral support at baseline and after 6 months of teduglutide (N=79). One case of off-label use was included. *PS* parenteral support



Fig. S2 Effectiveness evaluation for short bowel syndrome in adult patients with Crohn's disease. **a** Frequency distribution of parenteral support doses at baseline and after 6 months of teduglutide (N=41). **b** Number of days per week of parenteral support at baseline and after 6 months of teduglutide (N=41). Off-label data were not included. *PS* parenteral support



Fig. S3 Effectiveness evaluation for short bowel syndrome in adult patients without Crohn's disease. **a** Frequency distribution of parenteral support doses at baseline and after 6 months of teduglutide (N=38). **b** Number of days per week of parenteral support at baseline and after 6 months of teduglutide (N=38). One case of off-label use was included. *PS* parenteral support



Fig. S4 Effectiveness evaluation for children with short bowel syndrome, number of days per week of parenteral support at baseline (N=22) and after 6 months of teduglutide (N=23). Histograms of parenteral support volume were not created due to the small number of pediatric patients. Off-label data were not included. *PS* parenteral support